Ross O. Meyers, Ph.D.
Affiliations: | 2005 | University of Arizona, Tucson, AZ |
Area:
Pharmaceutical Chemistry, Nutrition, PharmacologyGoogle:
"Ross Meyers"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Robert T. Dorr | grad student | 2005 | University of Arizona | |
| (Anticancer structure -activity relationships of semi-synthetic analogs of nordihydroguaiaretic acid.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Meyers RO, Lambert JD, Hajicek N, et al. (2009) Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. Bioorganic & Medicinal Chemistry Letters. 19: 4752-5 |
| Pourpak A, Dorr RT, Meyers RO, et al. (2007) Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Investigational New Drugs. 25: 107-14 |
| Pourpak A, Meyers RO, Samulitis BK, et al. (2006) Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anti-Cancer Drugs. 17: 1179-84 |
| Lambert JD, Sang S, Dougherty A, et al. (2005) Cytotoxic lignans from Larrea tridentata. Phytochemistry. 66: 811-5 |
| Lambert JD, Zhao D, Meyers RO, et al. (2002) Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. Toxicon : Official Journal of the International Society On Toxinology. 40: 1701-8 |
| Lambert JD, Meyers RO, Timmermann BN, et al. (2001) tetra-O-methylnordihydroguaiaretic acid inhibits melanoma in vivo. Cancer Letters. 171: 47-56 |
| Lambert JD, Meyers RO, Timmermann BN, et al. (2001) Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. Journal of Chromatography. B, Biomedical Sciences and Applications. 754: 85-90 |
| Dorr RT, Meyers R, Snead K, et al. (1998) Analytical and biological inequivalence of two commercial formulations of the antitumor agent bleomycin. Cancer Chemotherapy and Pharmacology. 42: 149-54 |